In vitro antitumor potential of 4-BPRE, a butyryl aminophenyl ester of retinoic acid: Role of the butyryl group

Oncology Reports

Volumn 11, Issue 3, 2004, Pages 719-726

  Um, Soo Jong ^a   Han, Hye Sook ^a   Kwon, Youn Ja ^a   Park, Si Ho ^a   Bae, Tae Sung ^b   Rho, Young Soy ^b   Sin, Hong Sig ^a  

^a Sejong University   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

4 APRE; 4 BPRE; 4 HPR; Apoptosis; c Jun; Cytotoxicity; Histone deacetylase; Invasion; RAR; Retinoic acid; Sodium butyrate

Indexed keywords

4 (ACETYLAMINO)PHENYLRETINOATE; 4 AMINO 2 (BUTYRYLAMINO)PHENYL(2E,4E,6E,8E) 3,7 DIMETHYL 9 (2,6,6 TRIMETHYL 1 CYCLOHEXENYL) 2,4,6,8 NONATETRAENOATE; 4-(ACETYLAMINO)PHENYLRETINOATE; 4-AMINO-2-(BUTYRYLAMINO)PHENYL(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)-2,4,6,8-NONATETRAENOATE; ANTINEOPLASTIC AGENT; DNA FRAGMENT; DRUG DERIVATIVE; ESTER; GELATINASE A; HISTONE DEACETYLASE; HYDROXAMIC ACID; INTERSTITIAL COLLAGENASE; RETINOIC ACID; RETINOID; TRICHOSTATIN A;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL SEPARATION; CELL STRAIN COS1; CHEMICAL MODEL; CHEMISTRY; DOSE RESPONSE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SEPARATION; COS CELLS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTERS; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MODELS, CHEMICAL; RETINOIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRETINOIN;

EID: 4644335119     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gudas LJ, Sporn MB and Roberts AB: Cellular biology and biochemistry of the retinoids. In: The Retinoids: Biology, Chemistry and Medicine. 2nd edition. Sporn MB, Roberts AB and Goodman DS (eds.) Raven Press, New York, pp443-520, 1994.
2. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954, 1996.
3. Pfahl M: Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651-658, 1993.
4. Karin M, Liu ZG and Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
5. Altucci L and Gronemeyer H: The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181 -193, 2001.
6. Ulukaya E and Wood EJ: Fenretinide and its relation to cancer. Cancer Treat Rev 25: 229-235, 1999.
7. Veronesi U, De Palo G, Costa A, Formelli F and Decensi A: Chemoprevention of breast cancer with fenretinide. IARC Sci Publ 136: 87-94, 1996.
8. Pienta KJ, Esper PS, Zwas F, Krzeminski R and Flaherty KE: Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 20: 36-39, 1997.
9. Reynolds CP:. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep 2: 511-518, 2000.
10. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R and Hong WK: N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6: 2973-2979, 2000.
11. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A and Veronesi U: Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11: 2036-2042, 1993.
12. Hague A, Elder DJ, Hicks DJ and Paraskeva C: Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer 60: 400-406, 1995.
13. Soldatenkov VA, Prasad S, Voloshin Y and Dritschilo A: Sodium butyrate induces apoptosis and accumulation of ubiquitinated proteins in human breast carcinoma cells. Cell Death Differ 5: 307-312, 1998.
14. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG and Simons JW: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
15. Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Branner J, Thuroff JW, Lange PH and Vessella RL: Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 14: 501-508, 1999.
16. Candido EP, Reeves R and Davie JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14: 105-113, 1978.
17. Lea MA and Randolph VM: Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res 18: 2717-2722, 1998.
18. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoplosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
19. Vigushin DM and Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13, 2002.
20. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB and Donehower RC: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7: 3047-3055, 2001.
21. Warrell Jr RP, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
22. Yu KH, Weng LJ, Fu S, Piantadosi S and Gore SD: Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia 13: 1258-1265, 1999.
23. Buommino E, Pasquali D, Sinisi AA, Bellastella A, Morelli F and Metafora S: Sodium butyrate/retinoic acid costimulation induces apoptosis-independent growth arrest and cell differentiation in normal and ras-transformed seminal vesicle epithelial cells unresponsive to retinoic acid. J Mol Endocrinol 24: 83-94, 2000.
24. Demary K, Wong L and Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163: 103-107, 2001.
25. Pili R, Kruszewski MP, Hager BW, Lantz J and Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angioaenesis. Cancer Res 61: 1477-1485, 2001.
26. Boatright JH, Stodulkova E, Do VT, Padove SA, Nguyen HT, Borst DE and Nickerson JM: The effect of retinoids and butyrate on the expression of CRX and IRBP in retinoblastoma cells. Vision Res 42: 933-938, 2002.
27. Nudelman A and Rephaeli A: Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J Med Chem 43: 2962-2966, 2000.
28. Urn SJ, Lee SY, Kim EJ, Han HS, Koh YM, Hong KJ, Sin HS and Park JS: Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett 174: 127-134, 2001.
29. Urn SJ, Kim EJ, Hwang ES, Kim SJ, Namkoong SE and Park JS: Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int J Cancer 85: 416-423, 2000.
30. Takei I, Takagi M, Santavirta S, Ida H, Ishii M, Ogino T, Ainola M and Konttinen YT: Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints. J Biomed Mater Res 52: 613-620, 2000.
31. IARC: IARC Handbooks of Cancer Prevention. Vitamin A. Vol. 3. International Agency for Research on Cancer, Lyon, 1998.
32. Moon RC, Pritchard JF, Mehta RG, Nomides CT, Thomas CF and Dinger NM: Suppressions of rat mammary cancer development by 4-HPR following surgical removal of first palpable tumor. Carcinogenesis 10: 1645-1649, 1989.
33. Pienta KJ, Nguyen NM and Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53: 224-226, 1993.
34. Formelli F and Cleris L: Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53: 5374-5376, 1993.